Introduction On February 11, 2025, the U.S. Food and Drug Administration (FDA) announced the approval of mirdametinib, marketed under the brand name Gomecli. This approval marks a historic milestone in the management of neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibromas (PNs) – a rare and challenging condition. The mirdametinib FDA approval is a significant advancement …
Name of Drug : Penpulimab-kcqx Drug Category : Antineoplastic agent Form : Injection . Introduction : Nasopharyngeal carcinoma (NPC) is a rare cancer that arises in the nasopharynx, most often seen in the non-keratinizing form linked to the Epstein Barr virus. In April 2025, the FDA approved a promising immunotherapy: penpulimab KCQX, a next-generation PD1 …
Introduction : Lung cancer is one of the most challenging cancers to treat globally. Of its various forms, non-small cell lung cancer (NSCLC) is the most common, with many patients harboring specific genetic alterations such as ROS1 or NTRK fusions. This has opened the door to targeted therapies, and talatrectinib has emerged as a promising …
Introduction : Lung cancer is one of the most challenging cancers to treat, especially in its advanced stages. As scientists and pharmaceutical companies strive for better results, one promising treatment that has garnered attention in recent years is telisotuzumab adizutecan. This antibody-drug conjugate (ADC) is making waves in clinical trials for a targeted approach to …
Brand Name : Avmapki Fakzynja Co-pack Generic Name : avutometinib and defactinib Dosage form :Avmapki capsules , Fakzynja tablets . 🔹 Introduction : Ovarian cancer is one of the most challenging gynecologic cancers to treat, particularly when it comes to recurrent low-grade serous ovarian cancer (LGSOC) with KRAS mutations. On May 8, 2025, the FDA …
